Abstract
Head and neck squamous cell carcinoma (HNSCC) presents a complex clinical challenge due to its heterogeneous nature and diverse treatment responses. This systematic review critically appraises the performance of handcrafted radiomics (HC) and deep learning (DL) models in prognosticating outcomes in HNSCC patients treated with (chemo)-radiotherapy. A comprehensive literature search was conducted up to May 2023, identifying 23 eligible studies that met the inclusion criteria of methodological rigor and long-term outcome reporting. The review highlights the methodological variability and performance metrics of HC and DL models in predicting overall survival (OS), loco-regional recurrence (LRR) and distant metastasis (DM). While DL models demonstrated slightly superior performance metrics compared to HC models, the highest methodological quality was observed predominantly in studies using HC radiomics. The findings underscore the necessity for methodological improvements, including pre-registration of protocols and assessment of clinical utility, to enhance the reliability and applicability of radiomic-based prognostic models in clinical practice.
Competing Interest Statement
Andre Dekker is a founder, shareholder and employee of Medical Data Works B.V. All other authors do not have any competing interest.
Funding Statement
Authors acknowledge financial support from the NWO funded personal health Train for RAdiation oncology in India and the Netherlands: TRAIN project (629 002 212), the Stichting Hanarth Fonds and the Proton Therapy Research Infrastructure: ProTRAIT project (RUG 2017 8254) which is supported by the Dutch Cancer Society. Additionally, HMTT acknowledges the DBT/Wellcome Trust India Alliance Early Career Fellowship [Grant number: IA/E/18/1/504306] for the support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This review was performed in accordance with the relevant ethical guidelines and regulations of the institution, and did not require any informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.